Sanofi shares slipped as much as 2.1 percent after rival drugmaker Mylan said the PTO’s Patent Trial and Appeal Board ruled in its favor in inter partes review proceedings and found all claims of Sanofi’s Lantus formulation patents “unpatentable.”
The “favorable ruling that invalidates two Sanofi Lantus formulation patents is an important step forward in our journey to help address the needs of nearly 30 million Americans living with diabetes,” Mylan CEO Heather Bresch said in statement.
A Sanofi spokesman said in an email, “I want to stress that our scientists’ inventions are novel and nonobvious as recognized by the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.